Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide

Toxicology and Applied Pharmacology

Volumn 257, Issue 1, 2011, Pages 59-66

  Chien, Chia Wen ^a,b   Yao, Ju Hsien ^a,c   Chang, Shih Yu ^a   Lee, Pei Chih ^a,c   Lee, Te Chang ^a,c  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Arsenic trioxide; Chromatin relaxation; DNA damage; Suberoylanilide hydroxamic acid; Synergy

Indexed keywords

ARSENIC TRIOXIDE; PROTEIN P21; VORINOSTAT;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; COMET ASSAY; DNA DAMAGE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXIDES;

EID: 81255175566     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.018     Document Type: Article

References (61)

1. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19482-19487.
2. Aposhian H.V. Biochemical toxicology of arsenic. Reviews in Biochemical Toxicology 1989, 265-299. Elsevier Science Publishing Co., New York. E. Hodgson, J.R. Bend, R.M. Philpot (Eds.).
3. Ardalan B., Subbarayan P.R., Ramos Y., Gonzalez M., Fernandez A., Mezentsev D., Reis I., Duncan R., Podolsky L., Lee K., Lima M., Ganjei-Azar P. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin. Cancer Res. 2010, 16:3019-3027.
4. Berenson J.R., Matous J., Swift R.A., Mapes R., Morrison B., Yeh H.S. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res. 2007, 13:1762-1768.
5. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 2009, 15:3970-3977.
6. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
7. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
8. Cooper A.L., Greenberg V.L., Lancaster P.S., van Nagell J.R., Zimmer S.G., Modesitt S.C. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol. 2007, 104:596-601.
9. de Thé H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 2010, 10:775-783.
10. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5:981-989.
11. Emadi A., Gore S.D. Arsenic trioxide - an old drug rediscovered. Blood Rev. 2010, 24:191-199.
12. Fandy T.E., Shankar S., Ross D.D., Sausville E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7:646-657.
13. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193.
14. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009, 280:125-133.
15. Gazitt Y., Akay C. Arsenic trioxide: an anticancer missile with multiple warheads. Hematology 2005, 10:205-213.
16. Han Y.H., Kim S.Z., Kim S.H., Park W.H. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 2008, 270:40-55.
17. Hebbes T.R., Clayton A.L., Thorne A.W., Crane-Robinson C. Core histone hyperacetylation co-maps with generalized DNase I sensitivity in the chicken beta-globin chromosomal domain. EMBO J. 1994, 13:1823-1830.
18. Hei T.K., Filipic M. Role of oxidative damage in the genotoxicity of arsenic. Free Radic. Biol. Med. 2004, 37:574-581.
19. Huang L., Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 2000, 6:849-866.
20. Jang E.R., Lim S.J., Lee E.S., Jeong G., Kim T.Y., Bang Y.J., Lee J.S. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 2004, 23:1724-1736.
21. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., Peres L., Berthier C., Soilihi H., Raught B., de The H. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010, 18:88-98.
22. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S., Wissing M.D., Hedayati M., Shabbeer S., Mendonca J., Deangelis J., Marchionni L., Lin J., Hoti N., Nortier J.W., DeWeese T.L., Hammers H., Carducci M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 2010, 5:e11208.
23. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63:7291-7300.
24. Kim K.B., Bedikian A.Y., Camacho L.H., Papadopoulos N.E., McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005, 104:1687-1692.
25. Kitchin K.T., Conolly R. Arsenic-induced carcinogenesis-oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. Chem. Res. Toxicol. 2010, 23:327-335.
26. Kumar P., Gao Q., Ning Y., Wang Z., Krebsbach P.H., Polverini P.J. Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol. Cancer Ther. 2008, 7:2060-2069.
27. Lam H.K., Li K., Chik K.W., Yang M., Liu V.C., Li C.K., Fok T.F., Ng P.C., Shing M.M., Chuen C.K., Yuen P.M. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. Int. J. Oncol. 2005, 27:537-545.
28. Lee P.C., Kakadiya R., Su T.L., Lee T.C. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. Neoplasia 2010, 12:376-387.
29. Li Y., Qu X., Qu J., Zhang Y., Liu J., Teng Y., Hu X., Hou K., Liu Y. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009, 284:208-215.
30. Lin Y.L., Ho I.C., Su P.F., Lee T.C. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression. Toxicol. Appl. Pharmacol. 2006, 214:309-317.
31. Lin C.C., Hsu C., Hsu C.H., Hsu W.L., Cheng A.L., Yang C.H. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest. New Drugs 2007, 25:77-84.
32. Liu Y., Hock J.M., Sullivan C., Fang G., Cox A.J., Davis K.T., Davis B.H., Li X. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J. Cell. Biochem. 2010, 111:1546-1555.
33. Marchion D.C., Bicaku E., Daud A.I., Richon V., Sullivan D.M., Munster P.N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J. Cell. Biochem. 2004, 92:223-237.
34. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 2009, 107:600-608.
35. Miller W.H. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002, 7(Suppl. 1):14-19.
36. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
37. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., Richon V.M., Marks P.A., Anderson K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062.
38. Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992, 7:171-180.
39. Munshi A., Kurland J.F., Nishikawa T., Tanaka T., Hobbs M.L., Tucker S.L., Ismail S., Stevens C., Meyn R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005, 11:4912-4922.
40. Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther. 2006, 5:1967-1974.
41. Nagumo T., Takaoka S., Yoshiba S., Ohashi M., Shirota T., Hatori M., Isobe T., Tachikawa T., Shintani S. Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncol. 2009, 45:766-770.
42. Nawrocki S.T., Carew J.S., Douglas L., Cleveland J.L., Humphreys R., Houghton J.A. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res. 2007, 67:6987-6994.
43. Nian H., Delage B., Pinto J.T., Dashwood R.H. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 2008, 29:1816-1824.
44. Nolan L., Johnson P.W., Ganesan A., Packham G., Crabb S.J. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br. J. Cancer 2008, 99:689-694.
45. Roos W.P., Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 2006, 12:440-450.
46. Sato T., Suzuki M., Sato Y., Echigo S., Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int. J. Oncol. 2006, 28:1233-1241.
47. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
48. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., Stone R.M., Kalaycio M., Scheinberg D.A., Steinherz P., Sievers E.L., Coutre S., Dahlberg S., Ellison R., Warrell R.P. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 2001, 19:3852-3860.
49. Venugopal B., Evans T.R. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem. 2011, 18:1658-1671.
50. Vuky J., Yu R., Schwartz L., Motzer R.J. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest. New Drugs 2002, 20:327-330.
51. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 2010, 1:117-136.
52. Wang W., Qin S.K., Chen B.A., Chen H.Y. Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J. Gastroenterol 2001, 7:702-705.
53. Wu Y.C., Yen W.Y., Yih L.H. Requirement of a functional spindle checkpoint for arsenite-induced apoptosis. J. Cell. Biochem. 2008, 105:678-687.
54. Wu Y.C., Yen W.Y., Lee T.C., Yih L.H. Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis. Toxicol. Appl. Pharmacol. 2009, 236:231-238.
55. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
56. Yi J., Yang J., He R., Gao F., Sang H., Tang X., Ye R.D. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 2004, 64:108-116.
57. Yih L.H., Lee T.C. Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts. Mutat. Res. 1999, 440:75-82.
58. Yih L.H., Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 2000, 60:6346-6352.
59. Yih L.H., Tseng Y.Y., Wu Y.C., Lee T.C. Induction of centrosome amplification during arsenite-induced mitotic arrest in CGL-2 cells. Cancer Res. 2006, 66:2098-2106.
60. Zhang N., Wu Z.M., McGowan E., Shi J., Hong Z.B., Ding C.W., Xia P., Di W. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009, 100:2459-2464.
61. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., Liang W.X., Song A.X., Lallemand-Breitenbach V., Jeanne M., Zhang Q.Y., Yang H.Y., Huang Q.H., Zhou G.B., Tong J.H., Zhang Y., Wu J.H., Hu H.Y., de The H., Chen S.J., Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.